drugset / Trial / NCT07500207
A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
RandomizedParallel-groupSingle-blindPrevention
Summary
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group
Timeline
- Start
- 2026-03-04
- Primary completion
- 2026-05-25
- Completion
- 2027-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell) | Vaccine | — | — |
| Comparator | approved Rabies vaccine | Vaccine | — | — |